Upstream Bio (UPB) Competitors

Upstream Bio logo
$2.10 -0.05 (-2.33%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$2.10 0.00 (0.00%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UPB vs. SLDB, JANX, PRME, IRWD, and CGEM

Should you buy Upstream Bio stock or one of its competitors? Upstream Bio's main competitors and comparable companies include Solid Biosciences (SLDB), Janux Therapeutics (JANX), Prime Medicine (PRME), Ironwood Pharmaceuticals (IRWD), and Cullinan Therapeutics (CGEM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Upstream Bio compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Solid Biosciences has a beta of 2.65, meaning that its stock price is 165% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

Solid Biosciences presently has a consensus target price of $20.00, indicating a potential upside of 221.03%. Upstream Bio has a consensus target price of $26.67, indicating a potential upside of 1,169.84%. Given Upstream Bio's higher probable upside, analysts plainly believe Upstream Bio is more favorable than Solid Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.93
Upstream Bio
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

In the previous week, Upstream Bio had 10 more articles in the media than Solid Biosciences. MarketBeat recorded 12 mentions for Upstream Bio and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.74 beat Upstream Bio's score of 0.27 indicating that Solid Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Solid Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Upstream Bio
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Upstream Bio has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A-$174.32M-$1.79N/A
Upstream Bio$2.85M40.39-$143.44M-$3.02N/A

81.5% of Solid Biosciences shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 16.5% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Solid Biosciences has a net margin of 0.00% compared to Upstream Bio's net margin of -5,712.33%. Upstream Bio's return on equity of -57.09% beat Solid Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Solid BiosciencesN/A -66.95% -58.02%
Upstream Bio -5,712.33%-57.09%-54.69%

Summary

Solid Biosciences beats Upstream Bio on 8 of the 15 factors compared between the two stocks.

How does Upstream Bio compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Janux Therapeutics presently has a consensus price target of $36.92, indicating a potential upside of 244.75%. Upstream Bio has a consensus price target of $26.67, indicating a potential upside of 1,169.84%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Janux Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Janux Therapeutics
2 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.63
Upstream Bio
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Janux Therapeutics has higher revenue and earnings than Upstream Bio. Janux Therapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Janux Therapeutics$10M65.52-$113.62M-$1.59N/A
Upstream Bio$2.85M40.39-$143.44M-$3.02N/A

Janux Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -5,712.33%. Janux Therapeutics' return on equity of -11.80% beat Upstream Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Janux TherapeuticsN/A -11.80% -10.97%
Upstream Bio -5,712.33%-57.09%-54.69%

75.4% of Janux Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 16.5% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Janux Therapeutics had 3 more articles in the media than Upstream Bio. MarketBeat recorded 15 mentions for Janux Therapeutics and 12 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.27 beat Janux Therapeutics' score of 0.19 indicating that Upstream Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Janux Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Upstream Bio
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Janux Therapeutics has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

Summary

Janux Therapeutics beats Upstream Bio on 13 of the 16 factors compared between the two stocks.

How does Upstream Bio compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Prime Medicine has a net margin of -2,497.56% compared to Upstream Bio's net margin of -5,712.33%. Upstream Bio's return on equity of -57.09% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Prime Medicine-2,497.56% -222.88% -59.68%
Upstream Bio -5,712.33%-57.09%-54.69%

Prime Medicine presently has a consensus target price of $7.86, indicating a potential upside of 104.61%. Upstream Bio has a consensus target price of $26.67, indicating a potential upside of 1,169.84%. Given Upstream Bio's higher possible upside, analysts clearly believe Upstream Bio is more favorable than Prime Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prime Medicine
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
Upstream Bio
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Upstream Bio has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prime Medicine$4.63M150.88-$201.14M-$0.96N/A
Upstream Bio$2.85M40.39-$143.44M-$3.02N/A

In the previous week, Prime Medicine had 5 more articles in the media than Upstream Bio. MarketBeat recorded 17 mentions for Prime Medicine and 12 mentions for Upstream Bio. Prime Medicine's average media sentiment score of 0.57 beat Upstream Bio's score of 0.27 indicating that Prime Medicine is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prime Medicine
5 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Upstream Bio
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

70.4% of Prime Medicine shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 16.5% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Prime Medicine has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

Summary

Prime Medicine beats Upstream Bio on 11 of the 16 factors compared between the two stocks.

How does Upstream Bio compare to Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

In the previous week, Upstream Bio had 9 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 12 mentions for Upstream Bio and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.79 beat Upstream Bio's score of 0.27 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ironwood Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Upstream Bio
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ironwood Pharmaceuticals has higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ironwood Pharmaceuticals$296.15M2.72$24.02M$0.905.41
Upstream Bio$2.85M40.39-$143.44M-$3.02N/A

Ironwood Pharmaceuticals presently has a consensus price target of $6.23, indicating a potential upside of 27.99%. Upstream Bio has a consensus price target of $26.67, indicating a potential upside of 1,169.84%. Given Upstream Bio's higher probable upside, analysts plainly believe Upstream Bio is more favorable than Ironwood Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ironwood Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.57
Upstream Bio
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Ironwood Pharmaceuticals has a net margin of 37.38% compared to Upstream Bio's net margin of -5,712.33%. Upstream Bio's return on equity of -57.09% beat Ironwood Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ironwood Pharmaceuticals37.38% -81.40% 42.69%
Upstream Bio -5,712.33%-57.09%-54.69%

Ironwood Pharmaceuticals has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

Summary

Ironwood Pharmaceuticals beats Upstream Bio on 8 of the 14 factors compared between the two stocks.

How does Upstream Bio compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Cullinan Therapeutics presently has a consensus target price of $34.14, indicating a potential upside of 268.32%. Upstream Bio has a consensus target price of $26.67, indicating a potential upside of 1,169.84%. Given Upstream Bio's higher probable upside, analysts plainly believe Upstream Bio is more favorable than Cullinan Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cullinan Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Upstream Bio
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

In the previous week, Upstream Bio had 4 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 12 mentions for Upstream Bio and 8 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.81 beat Upstream Bio's score of 0.27 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cullinan Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Upstream Bio
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cullinan Therapeutics has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

Cullinan Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -5,712.33%. Upstream Bio's return on equity of -57.09% beat Cullinan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cullinan TherapeuticsN/A -59.06% -52.93%
Upstream Bio -5,712.33%-57.09%-54.69%

86.3% of Cullinan Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 16.5% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Upstream Bio has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan TherapeuticsN/AN/A-$219.88M-$3.07N/A
Upstream Bio$2.85M40.39-$143.44M-$3.02N/A

Summary

Upstream Bio beats Cullinan Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Upstream Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UPB vs. The Competition

MetricUpstream BioBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$117.85M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.6634.2628.24
Price / Sales40.3915.788.485.70
Price / CashN/A22.9521.0121.90
Price / Book0.494.184.463.72
Net Income-$143.44M-$24.15M$3.52B$393.10M
7 Day Performance-34.38%-7.78%-5.92%-5.76%
1 Month Performance-23.91%-5.96%-4.58%-7.14%
1 Year Performance-91.78%-8.08%-1.93%-7.46%

Upstream Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UPB
Upstream Bio
3.274 of 5 stars
$2.10
-2.3%
$26.67
+1,169.8%
-91.8%$117.85M$2.85MN/A75
SLDB
Solid Biosciences
3.0112 of 5 stars
$7.17
+2.1%
$20.00
+178.9%
+43.5%$783.51MN/AN/A121
JANX
Janux Therapeutics
2.7098 of 5 stars
$12.04
-5.6%
$36.92
+206.7%
-62.7%$780.70M$10MN/A114
PRME
Prime Medicine
3.4247 of 5 stars
$3.90
-9.3%
$7.41
+89.9%
+0.5%$779.92M$4.63MN/A146
IRWD
Ironwood Pharmaceuticals
3.0601 of 5 stars
$4.81
+2.8%
$6.23
+29.6%
+55.6%$773.32M$296.15M5.34100

Related Companies and Tools


This page (NASDAQ:UPB) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners